Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition
- 1 January 2015
- book chapter
- Published by Elsevier
- Vol. 125, 1-41
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout MiceDrug Metabolism and Disposition, 2012
- Brain Distribution of Cediranib Is Limited by Active Efflux at the Blood-Brain BarrierThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Collateral sensitivity as a strategy against cancer multidrug resistanceDrug Resistance Updates, 2012
- Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active EffluxThe Journal of Pharmacology and Experimental Therapeutics, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and RegulationPharmacological Reviews, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport FunctionDrug Metabolism and Disposition, 2009
- Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout miceAdvanced Drug Delivery Reviews, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008